Phio Pharmaceuticals - Warrants (21/12/2021) Operating Income

As of the most recent data (June 2026), PHIOW shows a operating income of $-2.5M. That compares with $-4M in the prior-year period — up 36.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PHIOW's operating income is now $-2.5M (was $-4M) — a 36.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Phio Pharmaceuticals - Warrants (21/12/2021) is outperforming or lagging.

Tracking PHIOW's operating income over time shows whether Phio Pharmaceuticals - Warrants (21/12/2021) is scaling, shrinking, or reshaping that part of the business. The current reading is $-2.5M That compares with $-4M in the prior-year period — up 36.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Phio Pharmaceuticals - Warrants (21/12/2021)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-2.5M) with ownership activity and broader fundamentals.

Phio Pharmaceuticals - Warrants (21/12/2021)'s operating income is $-2.5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.